Tsukuba, Japan

Tomoyuki Shibuguchi

USPTO Granted Patents = 2 

 

 

Average Co-Inventor Count = 9.3

ph-index = 1

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2016-2017

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Tomoyuki Shibuguchi

Introduction

Tomoyuki Shibuguchi is a notable inventor based in Tsukuba, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target neurological disorders. With a total of two patents to his name, Shibuguchi's work is recognized for its potential therapeutic applications.

Latest Patents

Shibuguchi's latest patents include a pyranodipyridine compound, which encompasses compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof. Another significant patent is for a tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative, which is represented by a specific formula (I) or a pharmaceutically acceptable salt thereof. This compound functions as an mGluR2 antagonist and is applicable as a therapeutic agent for neurological disorders related to glutamate dysfunction, including diseases such as Alzheimer's disease.

Career Highlights

Shibuguchi is currently employed at Eisai R&D Management Co., Ltd., where he continues to innovate and develop new pharmaceutical solutions. His work is instrumental in advancing the understanding and treatment of complex neurological conditions.

Collaborations

Throughout his career, Shibuguchi has collaborated with esteemed colleagues, including Mamoru Takaishi and Nobuhiro Sato. These collaborations have contributed to the success of his research and the development of his patented compounds.

Conclusion

Tomoyuki Shibuguchi's contributions to the field of pharmaceuticals highlight his innovative spirit and dedication to improving therapeutic options for neurological disorders. His patents reflect a commitment to advancing medical science and enhancing patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…